Peptides Eptifibati; Cas No 148031-34-9 white powder Peptide series
Product Name Eptifibati;?
Cas No. 148031-34-9
Molecular Formula C35H49N11O9S2
Molecular Weight 832.4
Appearance White slightly yellwish powder
Specific Rotation[20/D] -75.0～-95.0°(C=1,1%HAc) ?
Amino Acids composition ± 10%
Peptide Purity (By HPLC) ≥98% by area integration
Related Substance (By HPLC) Total Impurities (%)≤2.0%? Largest
Single Impurity (%)≤ 1.0%
Water Content (Karl Fischer) ≤8.0%
Peptide Content(N determination) ≥80%
Acetate Content ≤15%
IR spectrum in accordance
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also
co-promoted by Schering-Plough/Essex), is an antiplatelet drug of
the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a
cyclic heptapeptide derived from a protein found in the venom of
the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri).
It belongs to the class of the so-called
arginin-glycin-aspartat-mimetics and reversibly binds to platelets.
Eptifibatide has a short half-life. The drug is the third inhibitor
of GPIIb/IIIa that has found broad acceptance after the specific
antibody abciximab and the non-peptide tirofiban entered the global
Eptifibatide is used to reduce the risk of acute cardiac ischemic
events (death and/or myocardial infarction) in patients with
unstable angina or non-ST-segment-elevation (e.g., non-Q-wave)
myocardial infarction (i.e., non-ST-segment elevation acute
coronary syndromes) both in patients who are to receive non surgery
(conservative) medical treatment and those undergoing percutaneous
coronary intervention (PCI).
The drug is usually applied together with aspirin or clopidogrel
and (low molecular weight or unfractionated) heparin. Additionally,
the usual supportive treatment consisting of applications of
nitrates, beta-blockers, opioid analgesics and/or benzodiazepines
should be employed as indicated. Angiographic evaluation and other
intensive diagnostic procedures may be considered a first line task
before initiating therapy with eptifibatide.
The drug should exclusively be used in hospitalized patients both
because of the serious degree of patients' illness and because of
the possible side-effects of eptifibatide.
This product is pressurized prodrug hormone, vasopressin glycyl in
injection into the blood after enzymatic hydrolysis in the molecule
is produced a continuous low level. The portal venous pressure it
generates the desired effect, but the changes of arterial blood
pressure than the use of vasopressin after much smaller, and the
blood of a few do not increase the fibrinolytic. Push once its role
can be maintained for about 4 ~ 6h.
anti-aging agent and perhaps another tool to use within your
current peptide protocol. The fact that it has been legitimized
within the HRT community and is available via prescription also
means that the effects attributed to this peptide have been well
researched, studied and proven to work.